Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches? by Songmao Zheng, Rodney Prell, Jennifer Sheng, Yow‐Ming Wang, Lora Hamuro

Get full text

Nivolumab exposure–response analysis for adjuvant treatment of melanoma supporting a change in posology by Kinjal Sanghavi, Pradeep Vuppala, Vijay Ivaturi, Lora Hamuro, Amit Roy, Satyendra Suryawanshi

Get full text

Pediatric model‐based dose optimization using a pooled exposure–response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma by Shengnan Du, Yue Zhao, Zheyi Hu, Sihang Liu, Amit Roy, Jun Shen, Li Zhu, Lora Hamuro

Get full text

Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations—Going beyond the body‐size effect by Zheyi Hu, Sihang Liu, Yue Zhao, Shengnan Du, Lora Hamuro, Jun Shen, Amit Roy, Li Zhu

Get full text

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors by Aung Naing, Xiaoping Zhang, David S Hong, Sarina A Piha-Paul, Ruslan D Novosiadly, Shaun O'Brien, Rasika Suryawanshi, Rahul A Sheth, Blessie E Nelson, Amy Xu, Lora Hamuro, Derrick McKinley

Get full text

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S] by Yan G. Ni, Stefania Di Marco, Jon H. Condra, Laurence B. Peterson, Weirong Wang, Fubao Wang, Shilpa Pandit, Holly A. Hammond, Ray Rosa, Richard T. Cummings, Dana D. Wood, Xiaomei Liu, Matthew J. Bottomley, Xun Shen, Rose M. Cubbon, Sheng-ping Wang, Douglas G. Johns, Cinzia Volpari, Lora Hamuro, Jayne Chin, Lingyi Huang, Jing Zhang Zhao, Salvatore Vitelli, Peter Haytko, Douglas Wisniewski, Lyndon J. Mitnaul, Carl P. Sparrow, Brian Hubbard, Andrea Carfí, Ayesha Sitlani

Get full text